Increasing Prevalence of IBS to Augment Growth of the Irritable Bowel Syndrome Treatment Market
Irritable bowel syndrome (IBS) is among the common disorders of the large intestine. Signs and symptoms include gas, bloating, abdominal pain, cramping, and constipation or diarrhea, or both. A diagnosis is usually made centered on symptoms. Simple changes in diet and lifestyle often provide relief from IBS. Others need medication and counselling. Medications approved for treating IBS include Alosetron (Lotronex), Eluxadoline (Viberzi), Rifaximin (Xifaxan), Lubiprostone (Amitiza), and Linaclotide (Linzess). Competitive Analysis: Major players operating in the Irritable Bowel Syndrome Treatment Market are Synergy Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., GlaxoSmithKline Plc. Novartis AG, Astellas Pharma Inc., Ardelyx, Inc., Sucampo Pharmaceuticals, Inc., Abbott Laboratories, and Valeant Pharmaceuticals International, Inc. Major market players are adopting various strategies, such as for example research and development, to develop safe and effecti...